Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa

The purpose of this study to evaluate the long term safety, tolerability and efficacy of
adalimumab in subjects with moderate to severe HS. The clinical trial identifier is PIONEER
(OPEN-LABEL EXTENSION).

Inclusion Criteria:

- Subjects who previously participated in a prior Phase 3 Abbott HS study and:

1. Completed the study; or

2. Experienced a loss of response (LOR); or

3. Experienced Worsening or Absence of Improvement

Exclusion Criteria:

- Prior treatment with any other anti-TNF therapy (e.g., infliximab, etanercept), or
participation in an adalimumab trial other than a prior Phase 3 Abbott HS study.

- Subject received any oral antibiotic treatment for HS within 28 days prior to the
Baseline visit, except for antibiotics permitted in a prior Phase 3 Abbott HS study.

- Subject received oral concomitant analgesics (including opioids) for HS-related pain
within 14 days prior to the Baseline visit, except for permitted analgesics taken in
the prior Phase 3 Abbott HS study.